Research Progress on Vaccines of Porcine Circovirus Type 2
WANG Yi-ping, GUO Long-jun, TANG Qing-hai, LIU Chang-ming*
(Division of Swine Infectious Diseases, State Key Laboratory of Veterinary Biotechnology,
Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences,
Harbin 150001, China)
WANG Yi-Ping, GUO Long-Jun, TANG Qing-Hai, LIU Chang-Ming. Research Progress on Vaccines of Porcine Circovirus Type 2[J]. ACTA VETERINARIA ET ZOOTECHNICA SINICA, 2012, 43(9): 1337-1345.
［1］ALLAN G M，ELLIS J A. Porcine circoviruses：A review ［J］. Vet Diagn Invest，2000，12：3-14.［2］GUO L J，LU Y H，WEI Y W，et al. Porcine circovirus type 2 (PCV2)：genetic variation and newly emerging genotypes in China ［J］. Virol J，2010，7（1）：273.［3］SEGALES J，ALLAN G M，DOMINGO M. Porcine circovirus diseases ［J］. Anim Health Res Rev，2005，6（2）：119-142.［4］TISCHER I，GELDERBLOM H，VETTERMANN W，et al. A very small porcine virus with circular single-stranded DNA ［J］. Nature，1982，295：64-66.［5］CHEUNG A K. Transcriptional analysis of porcine circovirus Type 2 ［J］. Virology，2003，305（1）：168-180. ［6］NAWAGITGUL P，MOROZOW I，BOLIN S R，et al. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein ［J］. J Gen Virol，2000，81（9）：2281-2287.［7］LIU J，CHEN I，KWANG J. Characterization of a previously unidentified viral protein in porcine circovirus type 2-infected cells and its role in virus-induced apoptosis ［J］. J Virol，2005，79（13）：8262-8274.［8］RAMAMOORTHY S，MENG X J. Porcine circoviruses：a minuscule yet mammoth paradox ［J］. Anim Health Res Rev，2009，10（1）：1-20.［9］OPRIESSNIG T，MENG X J，HALBUR P G. Porcine circovirus type 2 associated disease：update on current terminology，clinical manifestations，pathogenesis，diagnosis，and intervention strategies ［J］. J Vet Diagn Invest，2007，19：591-615.［10］KEKARAINEN T，MCCULLOUGH K，FORT M，et al. Immune responses and vaccine-induced immunity against Porcine circovirus type 2 ［J］. Vet Immunol Immunop，2010，136：185-193.［11］BEACH N M，MENG X J. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2) ［J］. Virus Res，2012，164：33-42.［12］OPRIESSNIG T，PATTERSON A R，MADSON D M，et al. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccineinduced immunity on vaccination ［J］. Vet Microbiol，2010，142：177-183.［13］KURMANN J，SYDLER T，BRUGNERA E，et al. Vaccination of dams increases antibody titer and improves growth parameters in finisher pigs subclinically infected with porcine circovirus type 2 ［J］. Clin Vaccine Immunol，2011，18（10）：1644-1649.［14］FENAUX M，OPRIESSNIG T，HALBUR P G，et al. Two amino acid mutations in the capsid protein of type 2 porcine circovirus (PCV2) enhanced PCV2 replication in vitro and attenuated the virus in vivo ［J］. J Virol，2004，78（24）：13440-13446.［15］OPRIESSNIG T，PATTERSON A R，MADSON D M，et al. Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3 months post vaccination ［J］. Vaccine，2009，27：1002-1007.［16］FORT M，SIBILA M，PREZMARTN E，et al. One dose of a porcine circovirus 2 (PCV2) subunit vaccine administered to 3-week-old conventional piglets elicits cellmediated immunity and significantly reduces PCV2 viremia in an experimental model ［J］. Vaccine，2009，27（30）：4031-4037.［17］刘长明，陆月华，张超范，等. 猪圆环病毒2型重组Cap蛋白在昆虫杆状病毒中的表达 ［J］.中国预防兽医学报，2005，27（6）：479-482.［18］张家明. 猪圆环病毒2型ORF2基因在昆虫杆状病毒表达系统的表达及亚单位疫苗的初步研究 ［D］. 郑州：河南农业大学，2010.［19］WESLEY R D，TANG M，LAGER K M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus ［J］. Vaccine，2004，22（34）：27-34.［20］CHINSANGARAM J，MORAES M P，KOSTER M，et al. Novel viral disease control strategy：adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease ［J］. J Virol，2003，77（162）：1-5.［21］MASCOLA J R，SAMBOR A，BEAUDRY K，et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins ［J］. J Virol，2005，79（77）：1-9.［22］WANG X W，JIANG W M，JIANG P，et al. Construction and immunogenicity of recombinant adenovirus expressing the capsid protein of porcine circovirus 2 ( PCV2) in mice ［J］. Vaccine，2006，24(16)：3374-3380.［23］WANG X W，JIANG P，LI Y，et al. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2 ［J］. Vet Microbiol，2007，121（324）：215-224.［24］LIU G M，LUO M L，CHEN R A，et al. Construction and immunogenicity of recombinant adenovirus expressing ORF2 of PCV2 and porcine IFN-gamma ［J］. Vaccine，2011，29：8677-8682.［25］JU C，FAN H Y，TAN Y，et al. Immunogenicity of a recombinant pseudorabies virus expressing ORF1-ORF2 fusion protein of porcine circovirus type 2 ［J］. Vet Microbiol，2005，109：179-190.［26］SONG Y F，JIN M L，ZHANG S L，et al. Generation and immunogenicity of a recombinant pseudorabies virus expressing cap protein of porcine circovirus type 2 ［J］. Vet Microbiol，2007，119：97-104.［27］FAN Y，XIAO S，FANG L，et al. Efficient transduction of porcine kidney cells with pseudotype baculovirus ［J］. J Huazhong Agric Univ，2007，26：478-481.［28］FAN H Y，PAN Y H，FANG L R，et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice ［J］. J Virol Methods，2008，150：21-26.［29］PEI Y L，HODGINS D C，WU J Q，et al. Porcine reproductive and respiratory syndrome virus as a vector：Immunogenicity of green fluorescent protein and porcine circovirus type 2 capsid expressed from dedicated subgenomic RNAs ［J］. Virology，2009，389（122）：91-99.［30］GAO J M，WANG Y L，LIU Z Q，et al. Phage display and its application in vaccine design ［J］. Ann Microbiol，2010，60：13-19.［31］GAMAGE L N，ELLIS J，HAYES S. Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes ［J］.Vaccine，2009，27（47）：6595-6604.［32］DROUAULT S，CORTHIER G，EHRLICH S D，et al. Survival，physiology and lysis of Lactococcus lactis in the digestive tract ［J］. Appl Environ Microbiol，1999，65（11）：4881-4886.［33］WANG K，HUANG L H，KONG J，et al. Expression of the capsid protein of porcine circovirus type 2 in Lactococcus lactis for oral vaccination ［J］. J Virol Methods，2008，150：1-6.［34］STEVENSON A，ROBERTS M. Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC：improved immunogenicity using a Bvg-regulated promoter to express FrgC ［J］. Vaccine，2004，22：4300-4305.［35］KIM T，TOAN N T，SEO J，et al. Bordetella bronchiseptica aroA mutant as a live vaccine vehicle for heterologous porcine circovirus type 2 major capsid protein expression ［J］. Vet Microbiol，2009，138：318-324.［36］BUCAREY S A，NORIEGA J，REYES P，et al. The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts ［J］. Vaccine，2009，27：5781-5790.［37］KAMSTRUP S，BARFOED A M，FRIMANN T H，et al. Immunisation against PCV2 structural protein by DNA vaccination of mice ［J］. Vaccine，2004，22：1358-1361.［38］BLANCHARD P，MAHE D，CARIOLET R，et al. Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins ［J］. Vaccine，2003，21（31）：4565-4575.［39］SHEN H G，ZHOU J Y，HUANG Z Y，et al. Protective immunity against porcine circovirus 2 by vaccination with ORF2-based DNA and subunit vaccines in mice ［J］. J Gen Virol，2008，89：1857-1865.［40］FENAUX M，OPRIESSNIG T，HALBUR P G，et al. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs ［J］. J Virol，2004，78（12）：6297-6303.［41］ARAVINDARAM K，KUO T Y，LAN C W，et al. Protective immunity against porcine circovirus 2 in mice induced by a genebased combination vaccination ［J］. J Gene Med，2009，11（4）:288301.［42］SEGALS J，URNIZA A，ALEGRE A，et al. A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical，pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms ［J］. Vaccine，2009，27：7313-7321.［43］OPRIESSNIG T，PATTERSON A R，ELSENER J，et al. Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2) vaccination to protect pigs from experimental infection with PCV2 ［J］. Clin Vaccine Immunol，2008，15（3）：397-401.［44］OPRIESSNIG T，MADSON D M，PRICKETT J R，et al. Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection ［J］. Vet Microbiol，2008，131：103-114.［45］LIU X J，WANG X B，SONG Y，et al. A candidate inactivated chimeric vaccine PCV1-2 constructed based on PCV1 and PCV2 isolates originating in China and its evaluation in conventional pigs in regard to protective efficacy against PCV2 infection ［J］. Microbiol Immunol，2011，55：254-266.［46］BEACH N M，SMITH S M，RAMAMOORTHY S，et al. Chimeric porcine circoviruses (PCV) containing amino acid epitope tags in the C terminus of the capsid gene are infectious and elicit both antiepitope tag antibodies and anti-PCV type 2 neutralizing antibodies in pigs ［J］. J Virol，2011，85（9）：4591-4595.［47］HUANG L P，LU Y H，WEI Y W，et al. Construction and biological characterisation of recombinant porcine circovirus type 2 expressing the V5 epitope tag ［J］. Virus Res，2011，161（2）：115-123.
